Eyeing an accelerated BLA, PhaseBio says its monoclonal antibody reversed the dangerous effects of AstraZeneca's blood thinner

Nicole DeFeudis

Editor

A class of blood thinners called P2Y12 inhibitors has been used for the last couple decades to treat and prevent a range of cardiovascular conditions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eyeing an accelerated BLA, PhaseBio says its monoclonal antibody reversed the dangerous effects of AstraZeneca's blood thinner

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Eye­ing an ac­cel­er­at­ed BLA, Phase­Bio says its mon­o­clon­al an­ti­body re­versed the dan­ger­ous ef­fects of As­traZeneca's blood thin­ner

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Eyeing an accelerated BLA, PhaseBio says its monoclonal antibody reversed the dangerous effects of AstraZeneca's blood thinner